Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease
Keyword(s):
2018 ◽
Keyword(s):
2019 ◽
Vol 41
(05)
◽
pp. 526-533
Keyword(s):
Keyword(s):